Ollin details OLN324's head-to-head edge over faricimab in wAMD at ASRS
The Phase 1b JADE data Ollin previewed in March get their full airing at ASRS, setting up global Phase 3 trials in wet AMD and diabetic macular edema later this year.
Executive Summary
- Ollin is presenting the full dataset behind results it already disclosed months earlier, giving investors and clinicians their first detailed public look at how OLN324 compared to faricimab head-to-head.
- The trial reported an anatomic and safety edge over the approved comparator, with faster fluid resolution and no inflammatory safety signal, a profile that would support a differentiated Phase 3 positioning if it holds.
- This is a non-registrational Phase 1b readout being narrated in more depth, not a new efficacy result or a regulatory event; the real test comes when Phase 3 starts later this year.
- No other program in active development shares OLN324's dual VEGF and Ang2 bispecific design in this indication, leaving the comparison anchored to the approved standard of care rather than to a direct mechanistic rival.
The presentation
Ollin Biosciences, Inc. will present results from the randomized, head-to-head Phase 1b JADE trial evaluating OLN324 against faricimab (Vabysmo) in patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), in two oral sessions at the ASRS 44th Annual Scientific Meeting in Montreal on July 16, 2026. David Eichenbaum, M.D., will present the wAMD data and Veeral Sheth, M.D., will present the DME data. The trial, registered as NCT07484074, enrolled 164 patients and completed with a primary completion date of October 10, 2025. Ollin+1Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Scientific MeetingJul 13, 2026A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324NCT07484074
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What was already disclosed
Ollin first announced final Week 20 results from JADE in March 2026, reporting that OLN324 showed a favorable safety profile with zero cases of intraocular inflammation compared with one case for faricimab, a mean vision gain of 2.2 letters in wAMD, and roughly 50% greater reductions in pigment epithelial detachment thickness at Week 12 versus faricimab. Patients on OLN324 also showed higher rates of remaining retreatment-free through 12 weeks off treatment compared with faricimab. The trial's registered primary endpoint is adverse events, evaluated in a study designed to test safety, tolerability, pharmacokinetics, and exploratory efficacy rather than to establish a registrational efficacy claim. Ollin+1Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Scientific MeetingJul 13, 2026A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324NCT07484074
The design
JADE randomized patients into a faricimab active-comparator arm and two OLN324 experimental arms, with the primary endpoint set as adverse events collected through the study period. OLN324 is described as a next-generation VEGF/Ang2 bispecific antibody with higher Ang2 potency, increased molar dosing relative to faricimab and aflibercept (including Eylea HD), and a smaller protein format, delivered intravitreally. The trial was not registrational, and its 164-patient size and Phase 1b classification mean the ASRS presentation functions as a fuller unveiling of exploratory efficacy and safety findings rather than a new statistical readout. NCT07484074+1A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324NCT07484074Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Scientific MeetingJul 13, 2026
What comes next
Ollin has said it plans to initiate global Phase 3 trials of OLN324 in DME and wAMD in the second half of 2026, recruiting across North America, South America, Europe, Japan, China, and South Korea. That timeline makes the ASRS presentation a bridge between the completed Phase 1b program and the larger, registrational trials that will next test whether the anatomic and safety signals seen here translate into a vision-outcome advantage over the approved standard of care. OllinOllin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Scientific MeetingJul 13, 2026
Competitive positioning
No program tracked in the wet AMD or diabetic macular edema competitive set shares OLN324's VEGF/Ang2 bispecific mechanism, leaving faricimab, itself a VEGF-A/Ang2 bispecific antibody already approved and marketed, as the nearest comparator by mechanism class even though it is structured differently from OLN324. The broader wAMD and DME landscape includes gene-therapy, small-molecule, and antibody programs from sponsors including AbbVie, Adverum Biotechnologies, and 4D Molecular Therapeutics, none of which target the same VEGF/Ang2 bispecific pairing as OLN324. Given an established standard of care already delivered via the same route, the threshold for the Phase 3 program is replicating and extending the anatomic and durability edge over faricimab across a larger, longer, registrational population.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.